Search results for "MESH : Pregnancy"

showing 4 items of 4 documents

Very preterm birth: who has access to antenatal corticosteroid therapy?

2010

International audience; We describe the administration of antenatal corticosteroid therapy (ACT) for liveborn very preterm neonates in a population-based study. A total of 790 very preterm neonates (between 24 and 31 full weeks of gestation) were included in this regionally defined population of very preterm neonates in France. The main outcome measure was non-access to ACT. Data were analysed using logistic and polytomous models to control for neonatal and sociodemographic characteristics, mechanisms of very preterm birth and neonatal network organisation. As compared with level III, births in levels I-II maternity units were closely related to non-access to ACT (60.1% vs. 8.8%), but not t…

Gestational hypertensionPediatricsEpidemiologyMESH: Logistic ModelsHealth Services AccessibilityInfant Newborn Diseases[ SDV.CAN ] Life Sciences [q-bio]/CancerCohort Studies0302 clinical medicineMESH: PregnancyMESH : Health Services AccessibilityMESH: Risk FactorsAdrenal Cortex HormonesPregnancyRisk FactorsMESH: Maternal Health ServicesMESH : Socioeconomic FactorsMedicineChildbirthRupture of membranesMESH : FemaleMESH: Cohort StudiesMESH : Infant Newborn Diseaseseducation.field_of_studyMESH: Health Services Accessibility030219 obstetrics & reproductive medicineMESH: Middle AgedObstetricsMESH: Infant NewbornSmokingAge FactorsMiddle AgedMESH : AdultMESH : Risk Factors3. Good healthMESH : SmokingMESH : Infant PrematureMESH: Young AdultGestationFemaleFranceInfant PrematureMESH: Infant PrematureAdultmedicine.medical_specialtyMESH: SmokingMESH: Socioeconomic FactorsReferralAdolescentPopulationMESH : Young AdultMESH : Cohort StudiesMESH: Infant Newborn Diseases[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Infant NewbornMESH: Adrenal Cortex HormonesMESH : Adrenal Cortex Hormones03 medical and health sciencesYoung Adult030225 pediatricsMESH : AdolescentVery Preterm BirthHumansMaternal Health ServicesMESH : Middle AgededucationMESH : FranceMESH: AdolescentMESH: Age FactorsPregnancyMESH: Humansbusiness.industryMESH : HumansInfant NewbornMESH: Adultmedicine.diseaseMESH: FranceMESH : PregnancyLogistic ModelsSocioeconomic FactorsPediatrics Perinatology and Child HealthMESH : Age FactorsbusinessMESH: FemaleMESH : Maternal Health ServicesMESH : Logistic Models
researchProduct

The human near-term myometrial beta 3-adrenoceptor but not the beta 2-adrenoceptor is resistant to desensitisation after sustained agonist stimulatio…

2004

International audience; 1. In order to compare the beta(2)- and beta(3)-adrenoceptor (beta-AR) desensitisation process in human near-term myometrium, we examined the influence of a pretreatment of myometrial strips with either a beta(2)- or a beta(3)-AR agonist (salbutamol or SR 59119A, respectively, both at 10 microm, for 5 and 15 h) on the relaxation and the cyclic adenosine monophosphate (cAMP) production induced by these agonists. 2. To assess some of the mechanisms potentially implicated in the beta-AR desensitisation process, we studied the influence of such treatment on the number of beta(2)- and beta(3)-AR binding sites, the beta(2)- and beta(3)-AR transcripts expression and the pho…

MESH : Receptors Adrenergic beta-3MESH : Adrenergic beta-AgonistsMESH : Receptors Adrenergic beta-2Adrenergic beta-3 Receptor AgonistsMESH : Analysis of VarianceMESH : Dose-Response Relationship DrugMESH: Adrenergic beta-Agonists[SDV.BC]Life Sciences [q-bio]/Cellular BiologyIn Vitro TechniquesMESH: Dose-Response Relationship DrugMESH: PregnancyPregnancyMESH: Analysis of VarianceHumansMESH: Protein BindingAlbuterolMESH : FemaleMESH : AlbuterolAdrenergic beta-2 Receptor Agonists[SDV.BC] Life Sciences [q-bio]/Cellular BiologyAnalysis of VarianceMESH: HumansDose-Response Relationship Drug[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMESH : MyometriumMESH: AlbuterolMESH : HumansMESH : Protein BindingAdrenergic beta-AgonistsMESH : PregnancyReceptors Adrenergic beta-3PapersMyometriumMESH: MyometriumFemaleReceptors Adrenergic beta-2MESH: Receptors Adrenergic beta-3MESH: Receptors Adrenergic beta-2MESH: FemaleProtein Binding
researchProduct

Is the beta3-adrenoceptor (ADRB3) a potential target for uterorelaxant drugs?

2007

International audience; The management of premature birth still remains unsatisfactory. Since the relative lack of efficiency and/or safety of current tocolytic agents have been highlighted, it is necessary to develop new uterorelaxant drugs deprived of important maternal and foetal side effects. Our work reported in this review focuses on a potential new target for tocolytic drugs, the beta3-adrenoceptor (ADRB3). This third type of ADRB is shown to be present and functional in human myometrium. We demonstrated that ADRB3 agonists are able to inhibit in-vitro spontaneous contractions of myometrial strips, via a cyclic AMP-mediated pathway. Furthermore, we established that ADRB3 is the predo…

Muscle RelaxationMESH : Receptors Adrenergic beta-3MESH : Adrenergic beta-AgonistsUterusAdrenergic beta-3 Receptor AgonistsMESH: Adrenergic beta-AgonistsPharmacologyUterine contractionUterine Contraction0302 clinical medicineMESH: PregnancyMESH : UterusPregnancyObstetrics and GynaecologyMedicineMESH : FemaleMESH: Obstetric Labor Premature[ SDV.MHEP.GEO ] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetricsreproductive and urinary physiology0303 health sciencesMESH : MyometriumMyometriumMESH : Obstetric Labor PrematureObstetrics and GynecologyAdrenergic beta-Agonists3. Good healthmedicine.anatomical_structureMuscle relaxation030220 oncology & carcinogenesisTocolyticMESH: Uterine ContractionMyometriumMESH: MyometriumMESH: UterusFemalemedicine.symptomTocolytic agentmedicine.medical_specialtyAdrenergic receptorAdrenergic beta-3 Receptor Agonists[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetricsMESH : Muscle Relaxation03 medical and health sciencesObstetric Labor PrematureInternal medicineHumans030304 developmental biologyMESH: Humansbusiness.industryMESH : HumansUterus[SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetricsMESH : PregnancyEndocrinologyProceedingsReceptors Adrenergic beta-3MESH: Muscle RelaxationbusinessMESH: Receptors Adrenergic beta-3MESH: FemaleMESH : Uterine Contraction
researchProduct

Accuracy of blood transfusion in postpartum hemorrhage to assess maternal morbidity.

2012

International audience; OBJECTIVE: To measure the accuracy of blood transfusion (timing and number of blood units) in postpartum hemorrhage (PPH) in a perinatal network. STUDY DESIGN: (1) The ANONYMAT software system was used for anonymization and linkage of two large stand-alone databases, the Burgundy Perinatal Network (BPN) and the National Blood Centre (EFS) databases, which contain, respectively, clinical data from hospital discharges and information concerning any blood transfusion in France (considered as the gold standard database for identifying any transfusion). (2) Identification of prescriptions of at least one red blood cell (RBC) unit at the day of delivery (≥22 weeks) and up …

PediatricsBlood transfusionmedicine.medical_treatment0302 clinical medicineMESH: PregnancyBlood productPregnancyPerinatal networkMESH : Blood Transfusion[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : Female030212 general & internal medicineMESH : Obstetrics030219 obstetrics & reproductive medicineObstetricsMedical recordObstetrics and GynecologyMESH: Postpartum HemorrhageMESH: Predictive Value of Tests3. Good healthObstetricsBlood units[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleFranceMESH : Sensitivity and SpecificityMESH: Obstetricsmedicine.medical_specialty[SDV.IMM] Life Sciences [q-bio]/ImmunologyMaternal morbidityMESH: Blood TransfusionMESH : Postpartum HemorrhageSensitivity and Specificity03 medical and health sciencesPredictive Value of TestsmedicineHumansBlood TransfusionMESH : Predictive Value of TestsMedical prescriptionMESH : FranceMESH: Humansbusiness.industryPostpartum HemorrhageMESH : HumansGold standard (test)MESH: Sensitivity and SpecificityMESH: FranceMESH : PregnancyReproductive MedicinebusinessMESH: Female
researchProduct